Jun 18 |
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
|
Jun 6 |
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
|
May 17 |
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
|
May 9 |
Chemomab Therapeutics GAAP EPS of $0.01 beats by $0.02
|
May 9 |
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
|
May 8 |
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
|
May 2 |
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
|
Apr 24 |
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
|
Apr 18 |
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
|
Apr 2 |
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
|